Overview
Pemphigoid encompasses a group of autoimmune blistering disorders characterized by subepidermal blistering, often involving the skin and mucous membranes. These conditions include bullous pemphigoid, cicatricial pemphigoid, and less commonly, pemphigoid nodularis 13.Diagnosis
Clinical Presentation: Presence of subepidermal blisters, often with mucosal involvement (oral, conjunctival).
Immunodiagnostic Tests: Direct and indirect immunofluorescence microscopy to detect autoantibodies against basement membrane zone antigens.
Biopsy Analysis: Histopathological examination confirming subepidermal blistering and characteristic immune deposits 3.Management
First-Line Treatments:
- Corticosteroids: High-dose systemic glucocorticoids (e.g., prednisone) as initial therapy 3.
- Antibodies: Rituximab for recalcitrant cases, particularly in IgG-dominant pemphigoid diseases 2.
Adjunctive Treatments:
- Immunosuppressants: Addition of drugs like azathioprine, mycophenolate mofetil, or cyclophosphamide for refractory cases 3.
- Other Agents: Consideration of dapsone or tetracycline in some cases, though less commonly highlighted in pemphigoid compared to pemphigus 3.Special Populations
Elderly: Majority of cases occur in patients over 60 years, with higher incidence in elderly populations 13.
Comorbidities: Prevalence of other diseases, potentially drug-induced, noted in over 30% of patients 3.
Recalcitrant Cases: Rituximab shows efficacy in elderly patients with recalcitrant pemphigoid but may not be effective in IgA-dominant variants 2.Key Recommendations
Initiate with High-Dose Corticosteroids for systemic pemphigoid management to control blistering (Evidence: Strong 3).
Consider Rituximab for Recalcitrant Cases, especially in IgG-dominant pemphigoid, but be cautious as efficacy varies with IgA-dominant subtypes (Evidence: Moderate 2).
Monitor for Comorbidities and potential drug-induced etiologies in elderly patients presenting with pemphigoid (Evidence: Moderate 3).References
1 Tanaka H, Ishii T. Analysis of patients with drug-induced pemphigoid using the Japanese Adverse Drug Event Report database. The Journal of dermatology 2019. link
2 Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Frontiers in immunology 2018. link
3 Serwin AB, Bokiniec E, Piascik M, Masny D, Chodynicka B. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. Medical science monitor : international medical journal of experimental and clinical research 2007. link
4 Yu JT, Chong LY, Lee KC. A recalcitrant case of cicatricial pemphigoid. Hong Kong medical journal = Xianggang yi xue za zhi 2007. link